Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ramucirumab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04040361
What this trial is testing

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Who this might be right for
Non-small Cell Lung Cancer Stage IBNon-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage ⅢA
Masahiro Tsuboi 24
Early research (Phase 1)Study completedNCT02745769
What this trial is testing

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Who this might be right for
Advanced CancerColorectal CancerMantle Cell Lymphoma
Eli Lilly and Company 23
Testing effectiveness (Phase 2)Study completedNCT00533702
What this trial is testing

IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Who this might be right for
Metastatic Malignant Melanoma
Eli Lilly and Company 106
Testing effectiveness (Phase 2)Study completedNCT00683475
What this trial is testing

IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

Who this might be right for
Prostate Cancer
Eli Lilly and Company 138
Large-scale testing (Phase 3)Active Not RecruitingNCT02411448
What this trial is testing

Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Who this might be right for
Metastatic Non-Small Cell Lung Cancer
Eli Lilly and Company 545
Testing effectiveness (Phase 2)WithdrawnNCT03766607
What this trial is testing

Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Korean South West Oncology Group
Testing effectiveness (Phase 2)Study completedNCT03141034
What this trial is testing

Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastro-esophageal Junction Adenocarcinoma
Washington University School of Medicine 40
Early research (Phase 1)UnknownNCT05856864
What this trial is testing

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Who this might be right for
Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital 30
Large-scale testing (Phase 3)Study completedNCT02435433
What this trial is testing

Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein

Who this might be right for
Hepatocellular Carcinoma
Eli Lilly and Company 399
Large-scale testing (Phase 3)Study completedNCT01170663
What this trial is testing

Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

Who this might be right for
Gastric Cancer
Eli Lilly and Company 665
Testing effectiveness (Phase 2)Ended earlyNCT04145700
What this trial is testing

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Who this might be right for
Synovial Sarcoma
Eli Lilly and Company 23
Early research (Phase 1)Looking for participantsNCT05365581
What this trial is testing

ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 398
Testing effectiveness (Phase 2)Looking for participantsNCT04205968
What this trial is testing

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Who this might be right for
Metastatic Small Intestinal AdenocarcinomaStage III Small Intestinal Adenocarcinoma AJCC v8Stage IIIA Small Intestinal Adenocarcinoma AJCC v8+2 more
SWOG Cancer Research Network 94
Early research (Phase 1)Looking for participantsNCT06675136
What this trial is testing

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

Who this might be right for
Clinical Stage IVB Gastric Cancer AJCC v8Metastatic Gastric AdenocarcinomaMetastatic Malignant Neoplasm in the Peritoneum
City of Hope Medical Center 30
Testing effectiveness (Phase 2)Study completedNCT01246960
What this trial is testing

Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Who this might be right for
Stomach CancerEsophageal Cancer
Eli Lilly and Company 168
Testing effectiveness (Phase 2)WithdrawnNCT02831491
What this trial is testing

Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Stage IV Non-small Cell Lung Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Study completedNCT01567163
What this trial is testing

Ramucirumab and Docetaxel in Participants With Solid Tumors

Who this might be right for
Malignant Solid Tumor
Eli Lilly and Company 22
Large-scale testing (Phase 3)UnknownNCT02934464
What this trial is testing

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

Who this might be right for
Stomach Neoplasms
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 280
Testing effectiveness (Phase 2)Study completedNCT03689855
What this trial is testing

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

Who this might be right for
Non-small Cell Lung CancerNon Small Cell Lung CancerNSCLC
Washington University School of Medicine 21
Testing effectiveness (Phase 2)UnknownNCT04656002
What this trial is testing

As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

Who this might be right for
Gastric Cancer
Samsung Medical Center 43
Next Page